What Is Tirzepatide? A Research Overview

Tirzepatide is a synthetic dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist studied in metabolic and incretin research. The same molecule is approved as a prescription medicine under the brand names Mounjaro and Zepbound, but the material described here is a research-use-only (RUO) reference compound — it is not that medicine, is not an approved product in this form, and is not intended for human or veterinary use.

Quick facts

• Class: dual GIP and GLP-1 receptor agonist (incretin-mimetic peptide)
• Research focus: metabolic, incretin-signaling, and endocrine research
• Form: lyophilized powder, ≥99% HPLC purity, third-party tested
• Status: research use only — not for human or veterinary use

What is Tirzepatide?

Tirzepatide (research code LY3298176) is a single-chain synthetic peptide engineered to engage two incretin receptors at once: the GIP receptor and the GLP-1 receptor. Native incretin hormones — GIP and GLP-1 — are released by the gut and participate in the regulation of glucose-dependent insulin signaling. Tirzepatide was designed as a unimolecular agonist that activates both receptor pathways with a single molecule, which distinguishes it from selective GLP-1 receptor agonists that target only one pathway. As a research reference compound, it is used in laboratory and preclinical settings to study incretin receptor biology and dual-agonist signaling.

What does the research show?

In published pharmacology research, tirzepatide has been characterized as an “imbalanced” and “biased” dual agonist: it engages the GIP receptor comparably to native GIP while showing biased signaling at the GLP-1 receptor that favors cAMP generation over β-arrestin recruitment [1]. This receptor-level profile has been studied as a possible explanation for how dual agonism differs mechanistically from single GLP-1 receptor activation.

In clinical research, tirzepatide has been evaluated in large randomized trials. The SURPASS-2 trial studied once-weekly tirzepatide compared with semaglutide in adults with type 2 diabetes [2], and the SURMOUNT-1 trial studied once-weekly tirzepatide in adults with obesity [3]. These trials are reported here only to describe the published research record for the molecule; they do not describe this research-use-only material, and nothing here should be read as a benefit claim for any reader.

Mechanisms studied in the lab

• GIP receptor agonism — activation of the GIP receptor and downstream incretin signaling.
• GLP-1 receptor agonism — activation of the GLP-1 receptor, with biased cAMP-favoring signaling reported in vitro.
• Dual incretin signaling — combined engagement of both receptor pathways by a single molecule, a focus of structural and signaling studies.

Research status and safety

This tirzepatide material is supplied strictly for research use only (RUO). It is not for human or veterinary use, not for consumption, and is not an approved drug, food, or supplement in this form. While tirzepatide as an active pharmaceutical ingredient is FDA-approved within specific prescription products, the research material sold here is not an FDA-approved product and has not been evaluated by the FDA for any use in humans. Handling should be limited to qualified personnel in an appropriate laboratory environment, following standard safety practices for research chemicals.

Handling

Tirzepatide reference material is provided as a lyophilized (freeze-dried) powder for laboratory stability. For experimental work it is typically reconstituted with an appropriate solvent before in-vitro use. See our guide on how to reconstitute a research peptide for general laboratory handling information, and browse related GLP research peptides. Product specifications, purity data, and available quantities are listed on the product page: Tirzepatide — research-grade, ≥99% pure, third-party tested.

FAQ

How is tirzepatide different from semaglutide?
In published research, semaglutide is a selective GLP-1 receptor agonist, whereas tirzepatide is a dual agonist that engages both the GIP and GLP-1 receptors with a single molecule. This dual-receptor mechanism is the primary structural and pharmacological difference studied in the literature. Read about semaglutide.

What does “dual GIP/GLP-1 receptor agonist” mean?
It means the molecule binds and activates two different incretin receptors — the GIP receptor and the GLP-1 receptor — rather than just one.

Is this the same as Mounjaro or Zepbound?
No. Mounjaro and Zepbound are FDA-approved prescription medicines. The material described here is a research-use-only reference compound and is not for human use, not a medicine, and not interchangeable with any approved product.

References

1. Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PMC7526454
2. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503–515. PubMed 34170647
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed 35658024

For research use only. Not for human or veterinary use. Statements have not been evaluated by the FDA.